Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.54 |
| ▸ | TRAP1 | Q12931 | 7/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8422243 | 0.84 | DPP8 (0.59) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL8404042 | 0.83 | NOTUM (0.61) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL3427494 | 0.83 | DPP8 (0.57) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL8221404 | 0.83 | DDB1 (0.55) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL7946169 | 0.83 | TRAP1 (0.49) | TRAP1ABHD6NAMPTTAS1R3TAS1R1 | |
| SCHEMBL497487 | 0.81 | TRAP1 (0.56) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL3055486 | 0.81 | TRAP1 (0.56) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL30772456 | 0.81 | TRAP1 (0.56) | DPP8DPP9DPP7TRAP1ABHD6 | |
| SCHEMBL8192396 | 0.81 | NOTUM (0.61) | TRAP1HSP90B1NAMPTNPC1RAB9A | |
| SCHEMBL8227303 | 0.80 | TRAP1 (0.55) | DPP8DPP9DPP7TRAP1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8729014-B2 | Specific HCV NS3 protease inhibitors | RFS PHARMA, LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729014-B2 | Specific HCV NS3 protease inhibitors | RFS PHARMA, LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| WO-2009076173-A2 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009070689-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070692-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008021956-A2 | ACYLAMINOHETEROARYL HEPATITIS C VIRUS PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | DPP8 990/4885DPP9 1294/4885DPP7 1080/4885 |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | DPP8 123/4885DPP9 227/4885DPP7 106/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | DPP8 828/4885DPP9 1345/4885DPP7 1305/4885 |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | HPN, SPINT2, PRSS1 | DPP8 55/4885DPP9 70/4885DPP7 44/4885 |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | PRSS1, PPP4C, G6PC1 | DPP8 123/4885DPP9 162/4885DPP7 100/4885 |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | HPN, PRSS1, SERPINB1 | DPP8 139/4885DPP9 201/4885DPP7 156/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | DPP8 148/4885DPP9 179/4885DPP7 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.